Clinical Trial Update: PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating PRGN-2009 in combination with pembrolizumab for recurrent or metastatic cervical cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Carcinoma
• Hpv-related Carcinoma
• Hpv-related Malignancy

Drugs mentioned

• PRGN-2009
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Precigen, Inc | Conditions: Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Status: RECRUITING